Published in final edited form as:

J Pediatr Gastroenterol Nutr. 2013 August ; 57(2): 192–196. doi:10.1097/MPG.0b013e318293e1e1.

Use of a Non-invasive Test (Entero-test) in the Detection of *Helicobacter pylori* in Children in an Endemic Area in Colombia

Richard N Arboleda^{*}, Barbara G Schneider^{*}, Luis E Bravo[†], Judith Romero-Gallo^{*}, Richard M Peek Jr^{*}, Robertino M Mera^{*}, Maria Clara Yopez[‡], Cristina Campo[‡], and Pelayo Correa^{*}

^{*}Division of Gastroenterology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

[†]Department of Pathology, Universidad del Valle School of Medicine, Cali, Colombia

[‡]Universidad de Nariño, Pasto, Colombia

Abstract

Objectives—Gastric infection with *Helicobacter pylori* (*H. pylori*), a strong risk factor for gastric cancer, is highly prevalent in children residing in the Colombian Andes. We aimed to validate the use of the Entero-test to culture and genotype *H. pylori* strains from asymptomatic Colombian children.

Methods—Children (age 10–15y, n=110, 80 of which were *H. pylori*-positive by the urea breath test, or UBT) were subjected to the Entero-test, and strings were cultured and/or used for DNA extraction for PCR. These children had been treated for *H. pylori* in 2007. A second population of children (age 10–15y, n= 95), who had not been previously treated were also subjected to the Entero-test.

Results—Of UBT+ children in the treated group, 29/80 (36%) Entero-test samples were *H. pylori* culture positive; 29 additional string extracts were tested by PCR for the *H. pylori* virulence factors *cagA* and *vacA*. PCR from cultures and extracts yielded a Sensitivity of 74% and Specificity of 87%. In the untreated group, 16 of 94 UBT+ children (17%) produced Entero-tests that were culture positive. Fifty-eight of 94 (62%) string extracts were PCR positive for *cagA* and/or *vacA*. In previously treated children, *H. pylori* strains were more often the less virulent *vacA* s2 (P=0.001), m2 (P=0.006), and i2 genotypes (P=0.039).

Conclusions—The Entero-test may be used as a non-invasive test to detect *H. pylori* in asymptomatic children residing in high risk areas for gastric cancer. Treatment of *H. pylori* in children was associated with less virulent genotypes.

Gastric cancer is the fourth most commonly diagnosed cancer and second leading cause of cancer deaths worldwide, responsible for 738,000 deaths in 2008¹. In many parts of the world, such as the Andean regions of Latin America, this disease is the most common cause of cancer-related death. Identification of *Helicobacter pylori* (*H. pylori*) as a risk factor for gastric cancer² has revealed a new set of challenges for reducing the mortality of the disease. As part of ongoing studies in the natural history of infection, a cohort of children was previously established in the Andean region of Colombia, where *H. pylori* has a high prevalence in untreated children³, and the proportion of infected children increased with age (53% for 2-year-olds and 87% for 9 year-old asymptomatic children⁴). Large-scale

investigations of *H. pylori* in asymptomatic children in endemic areas have been limited due to the inability to obtain biopsies for ethical reasons. The Entero-test (HDC Corporation, San Jose, CA) has been validated as a non-invasive procedure to obtain *H. pylori* from gastric samples, with a variable diagnostic efficacy of culture and/or PCR ranging from 37–97%^{5, 6}. However, these studies have been performed in adults, and none have included children in an endemic area.

Previous studies have shown a difference in the virulence of strains in children depending on age and history of treatment. For example, some reports indicate that genotypes recovered from children are less virulent than those of adults⁷. The virulence-associated genes *cagA* and *vacA* play a role in the pathogenesis of *H. pylori*. The *cagA* gene, which encodes a 120 to 145 kDa protein, is a marker for the *cag* pathogenicity island (PAI) and is found in more than 50% of *H. pylori* strains⁸. The *cagA* gene, closely associated with the *vacA* *s1* genotype, is considered an inducer of pro-inflammatory cytokines in the gastric mucosa and is a risk factor for disease^{9, 10}. The *vacA* gene encodes an 88-kDa vacuolating cytotoxin (VacA) that forms pores in eukaryotic cell membranes¹¹. Within the *vacA* gene, three regions of marked sequence diversity can be distinguished: the *s* region (encoding the signal peptide) is present as either an *s1* or an *s2* allele, the intermediate region is present as either *i1* or *i2*, and the *m*-region (the middle region of the toxin) can be either *m1* or *m2*^{12–14}. The mosaic combination of *s* and *m* region alleles determines the production of the vacuolating cytotoxin and is associated with the pathogenicity of the bacterium. *VacA* *s1m1* strains have been associated with increased virulence and greater gastric epithelial damage and ulceration than *s2m2* strains^{12, 15}. Our aim was to validate the use of the Entero-test as a non-invasive test to identify the presence of *H. pylori* and evaluate the prevalence of *H. pylori* specific virulence genotypes in an endemic area.

Materials and Methods

Subjects

All subjects' parents provided informed consent for participation in accordance with the standard of the ethics review boards that approved this study: The Vanderbilt University Institutional Review Board and the Research Ethics Committee of the Universidad of Nariño. Two rural communities of children living in close proximity to each other with similar demographics in the endemic region of Nariño, Colombia, were selected. As part of an earlier study evaluating the effect of *H. pylori* infection on growth velocity, a cohort of asymptomatic children was established in both communities where one group of children (from towns of Nariño and Genoy) received a course of anti-*H. pylori* treatment in 2007 with poor results and the other (from towns of Laguna and Cabrera) was observed without treatment³. The two regions have predominantly rural populations of similar ancestry and socioeconomic status. Both groups continue to be monitored by UBT. Within 4–8 weeks of a UBT (delta over baseline > 5 parts per thousand was considered a positive test), subjects were offered the opportunity to participate in evaluation using the Entero-test. Children were recruited from both communities independent of UBT status. From the treated population, 110 children participated (80 UBT-positive and 30 UBT negative); from the untreated population, 95 participated (94 UBT positive and 1 UBT negative).

String Samples (Entero-test)

The pediatric Entero-test consists of a small plastic capsule attached to a 90 cm string made of absorbent material. The capsule is swallowed with water and dissolves in the stomach lumen, leaving a string that collects gastric juices that may harbor *H. pylori*. Before testing, to adjust the device for the individual, length measurements from the nose to laryngeal prominence to xyphoid process of each subject were recorded. Recorded measurements

were subtracted from the total length of the Entero-test (90cm) and the difference was excluded from the amount of string that could be swallowed, to reduce the risk of having the string enter the duodenum. Collection of samples in both populations was done by the same group of trained nurses who followed a uniform protocol for collection of samples, with the exception of the time the strings were left in the stomach, which was 30 minutes in the treated group. This initial time period was based on the study in adults by Yoshida et al¹⁶, who reported comparable sensitivity to studies using longer incubation times (1 hr)^{17–20}. Following our evaluation of results from this protocol, and in an attempt to increase the percentage of successful cultures, we used an incubation time of 45 minutes in the untreated group. After removing the strings, pH of fluid from the string was checked using pH paper strips. The distal portion (approximately 5 cm) of each string was placed in transport media (Thioglycolate + 20% glycerol) under sterile conditions, frozen and transferred in dry ice to Vanderbilt University for culture and PCR^{17, 21}. Frozen samples were thawed, plated on antibiotic plates (Trypticase soy agar + 5% sheep blood, Vancomycin 20ug/ml, Nalidixic Acid 10ug/ml, Bacitracin 30ug/ml, Amphotericin 2ug/ml) and placed in microaerobic conditions, using Campy Pak Plus envelopes (Difco/BBL, Lawrence, KS) at 37°C for 5–7 days. *H. pylori* colonies were identified on the basis of morphology and positive tests for urease, oxidase and Gram stain. Single colonies were then frozen until removed for DNA extraction.

Preparation of Genomic DNA from Entero-test Samples

DNA was extracted from single colony cultures of *H. pylori* using proteinase K [1 mg/mL in 50 mmol/L Tris/HCl buffer, pH 8.0, with 1 mmol/L EDTA (ethylene diamine tetraacetate)] and 0.45% Tween 20) at 52 °C overnight, followed by heating at 95 °C for 15 minutes to denature the proteinase K. DNA was extracted with phenol/chloroform and precipitated with ethanol. DNA pellets were washed with 70% ethanol and resuspended in Tris-EDTA buffer. For those subjects from whose Entero-tests no single colony cultures could be obtained, duplicate string segments were digested in 150 µL of proteinase K at 52 °C overnight. Digested material was heated at 95 °C for 15 minutes to denature the proteinase K, and the supernatant from this preparation was used as a template for PCR²².

PCR Amplification and Genotyping of Isolated Strains

To reduce the risk of reaction contamination, PCR assembly was performed in a dedicated area, filtered pipet tips were used, and all handling of PCR products was performed in a different laboratory. String extracts and DNA isolated from single colonies underwent PCR for virulence factors (*cagA* and *vacA* s, m, and i regions). The *cagA* gene was detected with primers (CagAF, CagAR) yielding amplicons of 183 bp²³. To amplify *vacA* s regions, primers VA1F and VA1R were selected, resulting in generation of fragments of 259 bp for type s1 variants or fragments of 286 bp for type s2 variants¹². For the detection of the m region of the *vacA* gene, a mixture of 2 forward primers (M2F1, M1F2) and 2 reverse primers (M2R1, M1R2) was used in a simplex PCR, resulting in amplification of fragments of 300 bp for m1 or 200 bp for m2 strains²⁴. For the i1 region of the *vacA* gene, primers V335F and C1R were used; V335 and C2R were used for the i2 region resulting in amplification of fragments of 426 bp and 432 bp, respectively¹¹.

H. pylori strain PZ5081 (genotype *cagA*+, *vacA* s1/m1) was used as a control for the presence of the *cagA* gene. Strains PZ5106 (genotype *cagA*+, *vacA* s1/m2/i1) and strain PZ5081 were used as controls for *vacA* genotypes. These positive controls for *cagA* and *vacA* genotypes had been validated by Sanger sequencing. Additionally, no-template controls were used in each experiment.

All PCR mixtures consisted of 0.2 mmol/L dNTP, 0.2 μ mol of each forward and reverse primer, 1.0 U of Amplitaq Gold DNA polymerase in a final volume of 40 μ L. Five microliters of DNA (20 to 50 ng) extracted from *H. pylori* cultures was added to each reaction mixture. The PCR programs for *cagA* and *vacA* i amplification consisted of 15 minutes at 95 °C, followed by 40 cycles of 1 minute at 94 °C, 1 minute at 55 °C, 1 minute at 72 °C, and a final incubation at 72 °C for 3 minutes. The amplification programs for *vacA* s and *vacA* m consisted of 15 minutes at 95 °C, 45 cycles at 95 °C for 1 minute for *vacA* s fragments (40 cycles at 95°C for 1 minute for *vacA* m), 1 minute at 52°C for *vacA* s fragments (58 °C for *vacA* m), 1 minute at 72 °C, and a final incubation at 72 °C for 5 minutes for *vacA* s (72°C for 3 minutes for *vacA* m). PCR products (10 μ L of each sample) were electrophoresed in 2% agarose gels stained with ethidium bromide for 1 hour at 100V.

Statistical Analysis

Sensitivity, specificity, and their 95% confidence intervals (CI) for PCR using Entero-test culture or string extracts versus UBT were calculated with standard epidemiologic methods. A chi square test was used to study associations between categorical variables such as genotypes (*cagA* +, *vacA* s1/s2, m1/m2, i1/i2), demographic parameters (gender), and outcomes of attempts at culture. A t-test was used to compare age distributions between the 2 populations. Fisher's exact test was used for comparing numbers of mixed infections in the two populations. We considered a *p* value of 0.05 or less statistically significant. Calculations were performed using STATA statistical software version 12 (College Station, TX).

Results

Patient Characteristics

In the treated group, the gender proportions were 55.5% male and 44.5% female; in the untreated group, the proportions were 49.5% male and 50.5% female. The average age was 12.50 years (95% CI, 12.27–12.74) in the treated group and 12.21 years (95% CI, 11.96–12.46) in the untreated group. Gender and age distributions between the treated and untreated groups were not significantly different. Prevalence of *H. pylori* infection, as measured by UBT, was 73% (95% CI, 63–81%) in the treated group and 99% (95% CI, 93–100%) in the untreated group.

Entero-test Culture Yield

Treated population—Culture yield for the Entero-test from UBT+ subjects was 36% (29/80). Extracts of Entero-test strings failing to produce cultures underwent PCR for virulence factors (*cagA*, *vacA*), with detection of either the *cagA* or *vacA* genes from string samples considered a positive result. Yield of PCR for UBT positive, culture negative samples was 59% (30/51). Analysis of combined culture and string extracts provided an Entero-test yield of 74% (59/80). Of tests from 30 UBT negative subjects, 3 nevertheless yielded cultures, and another produced positive PCR results from its string extract.

Untreated population—A total of 95 Entero-test strings were collected. Culture yield for the Entero-test using the longer incubation time was 17% (16/94 UBT positive children). Yield of PCR from string extracts from Entero-tests that did not produce single colony cultures was 74% (58/78 UBT positive children). Analysis of combined culture and string extracts provided an Entero-test yield of 79% (74/94 UBT positive children).

Culture yield was greater in the treated group (36%) when the Entero-test was left in the stomach for 30 minutes versus 45 minutes in the untreated group (17%). The longer time period was associated with an increase in contamination by other bacteria (*p*=0.0043).

However, the *H. pylori* detection rate among UBT+ children was not significantly different in the two groups (79% in the untreated group with 17% cultures vs. 74% in the treated group with 36% cultures, $p=0.48$)

Entero-test Sensitivity and Specificity

Treated population—In addition to the 80 Entero-test samples collected from UBT positive children, 30 Entero-test samples were obtained from UBT negative subjects. From those 30 samples, we cultured *H. pylori* from 3 samples and amplified *H. pylori* DNA (*cagA*) from an additional sample. See Table 1. Using UBT as the gold standard, the Entero-test had a Sensitivity of 74% (95% CI 63–83%), Specificity of 87% (95% CI, 69–96%), Positive Predictive Value (PPV) of 94% (95% CI, 85–98%), and Negative Predictive Value (NPV) of 55% (95% CI, 40–70%). However, if the 3 samples from UBT-negative subjects that produced *H. pylori* cultures are reclassified as true positives, the sensitivity, specificity, PPV and NPV are 75% (95% CI, 64–84%), 96% (95% CI, 81–99%), 98% (95% CI, 92–100%), and 55% (95% CI, 40–70%). If culture of *H. pylori* colonies alone (without analysis of string extracts) is compared to UBT results, we obtain a Sensitivity of 37% (95% CI, 26–48%), Specificity of 90% (95% CI, 73–98%), PPV of 91% (95% CI, 75–98%), and NPV of 35% (95% CI, 24–46%). All colonies produced genotyping results for at least one amplicon.

Untreated population—*H. pylori* prevalence rates were naturally so high in these communities that insufficient numbers of UBT negative children were available in the untreated community for calculating sensitivity, specificity, and positive and negative predictive values.

Genotyping of *H. pylori* Strains

Primers for *cagA* and *vacA* amplified the expected fragments of 183 bp for *cagA*, 259bp for *vacA* s1, and 286bp for *vacA* s2. Primers for *vacA* m1/m2 and i1/i2 amplified the expected fragments of 300 bp/ 200 bp and 426 bp/432 bp, respectively.

As shown in Table 2, in samples from UBT positive children in both groups, most samples were *cagA* positive (78% in the treated group and 80% in the untreated group). To eliminate strains that were false negatives due to lack of amplifiable DNA, we removed from the group of *cagA* negative strains those that had failed to provide detectable signal for any amplicon. The majority of the strains in both groups were *vacA* s1 and/or m1, but the previously treated group had a significantly lower proportion of virulent s1 ($p=0.001$), m1 ($p=0.006$) and i1 ($p=0.039$) strains compared to the untreated group. To examine the evidence for mixed infections, we evaluated PCR results from string extracts, using *vacA* s, m, and i assays, and counted the presence of any of the following: both s1 and s2, m1 and m2, or i1 and i2 for any extract, as a positive indicator for mixed infection. We found 14% (8/59) for the treated group and 1% (1/74) for the untreated group ($p=0.01$).

Discussion

The most widely used methods for the diagnosis of *H. pylori*, such as culture and histology, are sensitive and specific, but require invasive procedures and gastric biopsies. Among non-invasive procedures, the UBT is considered both sensitive and specific in the detection of *H. pylori*, but is not useful in the culture and characterization of the organism. The use of the Entero-test in adults has had a variable diagnostic utility for culture and/or PCR ranging from 37–97%⁶, but no published studies have included children. Our study is the first to evaluate the use of the Entero-test in a large cohort of asymptomatic children living in an endemic area at high risk for gastric cancer. When we combined results obtained from both

culture and string extracts, we obtained comparable diagnostic efficacy (74% and 79% for treated and untreated populations, respectively) to that of adult studies^{5, 6}.

The Entero-test allows an evaluation of *H. pylori* genotypes in children, without the selection bias inherent in the requirement for endoscopy. While bias may never be completely excluded, we think that it is likely that our study provides a less biased evaluation of *H. pylori* genotypes in asymptomatic children compared to methods employing endoscopy, which require that a child be symptomatic. Our Enterotest protocols differed in the length of time that the string was left in the stomach (30 min. in the treated population vs 45 min in the untreated population). Assuming that this difference is unlikely to introduce a bias that will affect genotypes observed, we can evaluate genotypes observed in the treated and untreated populations. In both groups, the prevalence of markers of virulence in asymptomatic children was high. The percentage of *cagA* positive samples from infected children was similar in both populations (78% in the treated group and 80% in the untreated group), while the percentage of *vacA* s1 alleles was 59% (treated group) and 91% (untreated group). Past studies in adults in Nariño, Colombia, have analyzed genotypes in infected patients for whom *H. pylori* therapy failed to eradicate the infection and found an increased proportion of low virulence strains, namely *cagA* negative and *vacA* s2/m2²⁵. Our findings in children are consistent with those in adults, supporting the idea that treatment, even if it fails to eradicate the infection, may select for less virulent strains. Since the antibiotic treatment three years prior to the current study, children had not been tested for antibiotic resistance in their infections, nor were infections classified as reinfections or recrudescence. Therefore selection of less virulent strains by treatment of children should be confirmed by following subjects at more frequent time points. Strains obtained by culture of Entero-tests may allow the possibility of addressing such questions in future studies in asymptomatic children.

Our method of evaluating mixed infections from the string extracts may be considered a conservative estimate, given that we are examining polymorphisms in only one gene, *vacA*, and that a high proportion of strains in these populations are of s1/ m1/ i1 genotypes. Nevertheless, it is interesting that the treated population of children shows significantly more mixed infections, consistent with the effect of treatment favoring the less virulent strains over the originally predominant high virulence *vacA* s1/m1/i1 strains.

The fraction of children in our untreated cohort that was *H. pylori* positive by UBT was quite high (99%), so that we were unable to calculate sensitivity, specificity, PPV or NPV with the untreated subjects. As we have reported earlier, the proportion of infected children in these mountain populations increases with age⁴. Our study suggests that this increase continues into the early teenage years. In developed countries, recent birth cohorts are increasingly failing to develop persistent *H. pylori* infections^{26, 27}, with sequelae that may predispose to asthma and esophageal diseases^{28–32}. However we see no evidence that *H. pylori* prevalence is decreasing in the rural populations that we have studied here, suggesting that the decreases in incidence rates of gastric cancer seen in developed countries are unlikely to be duplicated soon in these populations.

The percentages of *cagA* and *vacA* s1 strains are higher than those reported from children in other countries, even including symptomatic children. In gastric biopsies from symptomatic Portuguese children, *cagA* was detected in 36.1%, and *vacA* s1 was detected in 32.7% of children³³. Lower frequencies of both *cagA* (47%) and *vacA* s1 (58%) have been reported in gastric biopsy isolates from Mexican children with recurrent abdominal pain, but no peptic ulceration³⁴. The findings in our study indicate the presence of virulent strains in asymptomatic children in a population with a high incidence of gastric cancer in adults³⁵. High prevalence of virulent genes in asymptomatic children may contribute to the high

incidence of gastric cancer in adulthood and indicates the importance of early detection of *H. pylori*, larger epidemiological studies, and continued surveillance. In conclusion, the Entero-test may be used as a non-invasive test to detect *H. pylori* in asymptomatic children residing in areas of high incidence of gastric cancer. Technical improvements to increase the sensitivity and negative predictive value of the Entero-test would be beneficial to increase its utility for detecting *H. pylori* in these high risk populations.

REFERENCES

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev.* 2010; 19:1893–1907. [PubMed: 20647400]
2. IARC Working Group. IARC monograph on the evaluation of carcinogenic risks to humans: Schistosomes, liver flukes and *Helicobacter pylori*. International Agency for Research on Cancer. 1994
3. Goodman KJ, Correa P, Mera R, Yopez MC, Ceron C, Campo C, Guerrero N, Sierra MS, Bravo LE. Effect of *Helicobacter pylori* infection on growth velocity of school-age Andean children. *Epidemiology.* 2011; 22:118–126. [PubMed: 21068668]
4. Goodman KJ, Correa P, Tengana Aux HJ, Ramirez H, JP D, Guerrero Pepinosa O, Lopez Quinones M, Collazos Parra T. *Helicobacter pylori* infection in the Colombian Andes: A population-based study of transmission pathways. *Am J Epidemiol.* 1996:290–299. [PubMed: 8686698]
5. Torres J, Camorlinga M, Perez-Perez G, Gonzalez G, Munoz O. Validation of the string test for the recovery of *Helicobacter pylori* from gastric secretions and correlation of its results with urea breath test results, serology, and gastric pH levels. *J Clin Microbiol.* 2001; 39:1650–1651. [PubMed: 11283108]
6. Velapatino B, Balqui J, Gilman RH, Bussalleu A, Quino W, Finger SA, Santivanez L, Herrera P, Piscocya A, Valdivia J, Cok J, Berg DE. Validation of string test for diagnosis of *Helicobacter pylori* infections. *J Clin Microbiol.* 2006; 44:976–980. [PubMed: 16517886]
7. Torres J, Perez-Perez G, Goodman KJ, Atherton JC, Gold BD, Harris PR, la Garza AM, Guarner J, Munoz O. A comprehensive review of the natural history of *Helicobacter pylori* infection in children. *Arch Med Res.* 2000; 31:431–469. [PubMed: 11179581]
8. Covacci A, Censini S, Bugnoli M, Petracca R, Burrone D, Macchia G, Massone A, Papini E, Xiang Z, Figura N, et al. Molecular characterization of the 128-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. *Proc Natl Acad Sci U S A.* 1993; 90:5791–5795. [PubMed: 8516329]
9. Blaser MJ, Perez-Perez GI, Kleanthou TL, Cover RM, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with *Helicobacter pylori* strains possessing *cagA* is associated with an increased risk of developing adenocarcinoma of the stomach. *Cancer Res.* 1995; 55:2111–2115. [PubMed: 7743510]
10. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, De Boer W, Quint W. Clinical relevance of the *cagA*, *vacA*, and *iceA* status of *Helicobacter pylori*. *Gastroenterology.* 1998; 115:58–66. [PubMed: 9649459]
11. Cover TL. The vacuolating cytotoxin of *Helicobacter pylori*. *Mol Microbiol.* 1996; 20:241–246. [PubMed: 8733223]
12. Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific *vacA* types with cytotoxin production and peptic ulceration. *J Biol Chem.* 1995; 270:17771–17777. [PubMed: 7629077]
13. van Doorn LJ, Figueiredo C, Megraud F, Pena S, Midolo P, Queiroz DM, Carneiro F, Vanderborcht B, Pegado MD, Sanna R, De Boer W, Schneeberger PM, Correa P, Ng EK, Atherton J, Blaser MJ, Quint WG. Geographic distribution of *vacA* allelic types of *Helicobacter pylori*. *Gastroenterology.* 1999; 116:823–830. [PubMed: 10092304]
14. Rhead JLD, Hohammad M. A new *Helicobacter pylori* vacuolating cytotoxin determinant, the Intermediate region, Is associated with gastric cancer. *Gastroenterology.* 2007; 133:926–936. [PubMed: 17854597]

15. van Doorn LJ, Figueiredo C, Sanna R, Pena S, Midolo P, Ng EK, Atherton JC, Blaser MJ, Quint WG. Expanding allelic diversity of *Helicobacter pylori* vacA. J Clin Microbiol. 1998; 36:2597–2603. [PubMed: 9705399]
16. Yoshida H, Hirota K, Shiratori Y, Nihei T, Amano S, Yoshida A, Kakwamata O, Omata M. Use of a gastric juice-based PCR assay to detect *Helicobacter pylori* infection in culture-negative patients. J Clin Microbiol. 1998; 36:317–320. [PubMed: 9431979]
17. Windsor HM, Abioye-Kuteyi EA, Marshall BJ. Methodology and transport medium for collection of *Helicobacter pylori* on a string test in remote locations. Helicobacter. 2005; 10:630–634. [PubMed: 16302991]
18. Wang SW, Yu FJ, Lo YC, Yang YC, Wu MT, Wu IC, Lee YC, Jan CM, Wang WM, Wu DC. The clinical utility of string-PCR test in diagnosing *Helicobacter pylori* infection. Hepatogastroenterology. 2003; 50:1208–1213. [PubMed: 14571700]
19. Leodolter A, Wolle K, von Arnim U, Kahl S, Treiber G, Ebert MP, Peitz U, Malfertheiner P. Breath and string test: a diagnostic package for the identification of treatment failure and antibiotic resistance of *Helicobacter pylori* without the necessity of upper gastrointestinal endoscopy. World J Gastroenterol. 2005; 11:584–586. [PubMed: 15641151]
20. Leong RW, Lee CC, Ling TK, Leung WK, Sung JJ. Evaluation of the string test for the detection of *Helicobacter pylori*. World J Gastroenterol. 2003; 9:309–311. [PubMed: 12532455]
21. Sicinschi LA, Correa P, Peek RM, Camargo MC, Piazuelo MB, Romero-Gallo J, Hobbs SS, Krishna U, Delgado A, Mera R, Bravo LE, Schneider BG. CagA C-terminal variations in *Helicobacter pylori* strains from Colombian patients with gastric precancerous lesions. Clin Microbiol Infect. 2010; 16:369–378. [PubMed: 19456839]
22. Sicinschi LA, Correa P, Peek RM Jr, Camargo MC, Delgado A, Piazuelo MB, Romero-Gallo J, Bravo LE, Schneider BG. *Helicobacter pylori* genotyping and sequencing using paraffin-embedded biopsies from residents of colombian areas with contrasting gastric cancer risks. Helicobacter. 2008; 13:135–145. [PubMed: 18321303]
23. Akopyants NS, Clifton SW, Kersulyte D, Crabtree JE, Youree BE, Reece CA, Bukanov NO, Drazek ES, Roe BA, Berg DE. Analyses of the cag pathogenicity island of *Helicobacter pylori*. Mol Microbiol. 1998; 28:37–53. [PubMed: 9593295]
24. Koehler CI, Mues MB, Dienes HP, Kriegsmann J, Schirmacher P, Odenthal M. *Helicobacter pylori* genotyping in gastric adenocarcinoma and MALT lymphoma by multiplex PCR analyses of paraffin wax embedded tissues. Mol Pathol. 2003; 56:36–42. [PubMed: 12560462]
25. Correa P, van Doorn LJ, Bravo JC, Ruiz B, Bravo LE, Realpe JL. Unsuccessful treatment results in survival of less virulent genotypes of *Helicobacter pylori* in Colombian patients. Am J Gastroenterol. 2000; 95:564–566. [PubMed: 10685783]
26. Elitsur Y, Dementieva Y, Rewalt M, Lawrence Z. *Helicobacter pylori* infection rate decreases in symptomatic children: a retrospective analysis of 13 years (1993–2005) from a gastroenterology clinic in West Virginia. J Clin Gastroenterol. 2009; 43:147–151. [PubMed: 18779740]
27. Rehnberg-Laiho L, Rautelin H, Koskela P, Sarna S, Pukkala E, Aromaa A, Knekt P, Kosunen TU. Decreasing prevalence of *Helicobacter* antibodies in Finland, with reference to the decreasing incidence of gastric cancer. Epidemiol Infect. 2001; 126:37–42. [PubMed: 11293681]
28. de Martel C, Llosa AE, Farr SM, Friedman GD, Vogelstein JH, Orentreich N, Corley DA, Parsonnet J. *Helicobacter pylori* infection and the risk of development of esophageal adenocarcinoma. J Infect Dis. 2005; 191:761–767. [PubMed: 15688293]
29. Koster ED. Adverse events of HP eradication: long-term negative consequences of HP eradication. Acta Gastroenterol Belg. 1998; 61:350–351. [PubMed: 9795471]
30. Chen Y, Blaser MJ. Inverse associations of *Helicobacter pylori* with asthma and allergy. Arch Intern Med. 2007; 167:821–827. [PubMed: 17452546]
31. Vaezi MF, Falk GW, Peek RM, Vicari JJ, Goldblum JR, Perez-Perez GI, Rice TW, Blaser MJ, Richter JE. CagA-positive strains of *Helicobacter pylori* may protect against Barrett's esophagus. Am J Gastroenterol. 2000; 95:2206–2211. [PubMed: 11007219]
32. Loffeld RJLF, Werdmuller BFM, Kuster JG, Pérez-Pérez GI, Blaser MJ, Kuipers EJ. Colonization with cagA-positive *Helicobacter pylori* strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion. 2000; 62:95–99. [PubMed: 11025356]

33. Lopes AI, Palha A, Monteiro L, Olcastro M, Pelerito A, Fernandes A. *Helicobacter pylori* genotypes in children from a population at high gastric cancer risk: no association with gastroduodenal histopathology. *Am J Gastroenterol*. 2006; 101:2113–2122. [PubMed: 16848806]
34. Gonzalez-Valencia G, Atherton JC, Munoz O, Dehesa M, la Garza AM, Torres J. *Helicobacter pylori vacA* and *cagA* genotypes in Mexican adults and children. *J Infect Dis*. 2000; 182:1450–1454. [PubMed: 11023467]
35. Correa P, Cuello C, Duque E, Burbano LC, Garcia FT, Bolanos O, Brown C, Haenszel W. Gastric cancer in Colombia. III. Natural history of precursor lesions. *J Natl Cancer Inst*. 1976; 57:1027–1035. [PubMed: 1003539]

TABLE 1

Diagnostic efficacy of the Entero-test

Treated Group Entero-test Results	Urea Breath Test		Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	PPV (%) (95% CI)	NPV (%) (95% CI)
	Positive	Negative				
Culture/Extract Positive	59	4	63	74 (63–83)	87 (69–96)	94 (85–98)
Culture/Extract Negative	21	26	47			55 (40–70)
Total	80	30	110			

CI: Confidence interval; PPV: positive predictive value; NPV: negative predictive value.

TABLE 2

Genotypes of *H. pylori* Strains from UBT positive subjects:

Gene (<i>cagA</i>)	Treated N (%)	Untreated N (%)	χ^2 -value
Positive	46 (78)	59 (80)	0.80
Negative	13 [*] (22)	15 [*] (20)	
Total	59	74	
Gene (<i>vacA</i>)			
<i>s1</i>	32 (59)	62 (91)	0.001 ^{**}
<i>s2</i>	15 (28)	6 (9)	
<i>s1/s2</i>	7 (13)	0 (0)	
Total	54	68	
<i>m1</i>	38 (60)	54 (90)	0.006 ^{**}
<i>m2</i>	17 (31)	5 (8)	
<i>m1/m2</i>	0 (0)	1 (2)	
Total	55	60	
<i>i1</i>	18 (72)	28 (97)	0.039 [§]
<i>i2</i>	6 (24)	1 (3)	
<i>i1/i2</i>	1 (4)	0 (0)	
Total	25	29	

* Analysis excludes samples providing no signal for any virulence gene, as those are likely to be negative for technical reasons related to insufficient amplifiable DNA;

χ^2 : Chi square;

** Statistical Significance,

[§] Statistical significance if i2 and i1/i2 are combined.